UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
Clinical trial NCT03538314 · COMPLETED
Trial details
- NCT number
- NCT03538314
- Sponsor
- Ultimovacs ASA
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-09
- Primary completion
- 2022-10-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.